Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 3
Submit an article Journal homepage
693
Views
10
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

A single-institution retrospective analysis of outcomes for stage I–II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy

Michael S. BinkleyDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA
,
Susan M. HinikerDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA
,
Sharon WuDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA
,
Yasodha NatkunamDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA
,
Erik S. MittraDepartment of Radiology, Stanford University School of Medicine, Stanford, CA, USA
,
Ranjana H. AdvaniDepartment of Medicine, Division of Medical Oncology, Stanford University School of Medicine, Stanford, CA, USA
&
Richard T. HoppeDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USACorrespondence[email protected]
 show all
Pages 604-608 | Received 17 Apr 2015, Accepted 24 Jun 2015, Published online: 28 Sep 2015

References

  • Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’‘s Lymphoma Classification Project. J Clin Oncol 1998;16:2780–2795.
  • A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909–3918.
  • Savage KJ. Primary mediastinal large B-cell lymphoma. Oncologist 2006;11:488–495.
  • Savage KJ, Al-Rajhi N, Voss N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 2006;17:123–130.
  • Meier C, Hoeller S, Bourgau C, et al. Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Mod Pathol 2009;22:476–487.
  • Hoeller S, Zihler D, Zlobec I, et al. BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin's lymphoma from primary mediastinal large B-cell lymphoma. Histopathology 2010;56:217–228.
  • Soumerai JD, Hellmann MD, Feng Y, et al. Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. Leuk Lymphoma 2014;55:538–543.
  • Avigdor A, Sirotkin T, Kedmi M, et al. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma. Ann Hematol 2014;93:1297–1304.
  • Rieger M, Osterborg A, Pettengell R, et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol 2011;22:664–670.
  • Zinzani PL, Broccoli A, Casadei B, et al. The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients. Hematol Oncol 2014; [Epub ahead of print].
  • Martelli M, Ceriani L, Zucca E, et al. [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal LymphomaStudy Group IELSG-26 Study. J Clin Oncol 2014;32:1769–1775.
  • Filippi AR, Piva C, Giunta F, et al. Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy. Int J Radiat Oncol Biol Phys 2013;87:311–316.
  • Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013;368:1408–1416.
  • Meignan M, Barrington S, Itti E, et al. Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3–5 October 2012. Leuk Lymphoma 2014;55:31–37.
  • Dunleavy K, Pittaluga S, Janik J, et al. Primary mediastinal large B-cell lymphoma (PMBL) outcome is significantly improved by the addition of rituximab to dose adjusted (DA)-EPOCH and overcomes the need for radiation. Blood 2005;106(Suppl):929 (Abstr).
  • Pinnix CC, Dabaja B, Ahmed MA, et al. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by (18)fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys 2015;92:113–121.
  • Nagle SJ, Chong EA, Chekol S, et al. The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma. Cancer Med 2015;1:7–15.
  • Vassilakopoulos TP, Pangalis GA, Polliack A. A “PET” topic in primary mediastinal large B-cell lymphoma: positive or negative, and how to handle it in the end. Leuk Lymphoma 2015;56:3–5.
  • Cheah CY, Hofman MS, Seymour JF, et al. The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review. Leuk Lymphoma 2015;56:49–56.
  • Duehrsen U, Huttmann A, Muller S, et al. Positron Emission Tomography (PET) guided therapy of aggressive lymphomas – a randomized controlled trial comparing different treatment approaches based on interim PET results (PETAL Trial). Blood 2014;;124:391 (Abstr).
  • Sehn LH. Chemotherapy alone for localized diffuse large B-cell lymphoma. Cancer J 2012;18:421–426.
  • Gharwan H, Dunleavy K, Shovlin M, et al. Study on the fertility status of females with primary mediastinal B-cell lymphoma following treatement with dose-adjusted epoch-rituximab. Blood 2013;122:1779 (Abstr).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.